Opinion|Videos|July 4, 2024

Tailoring CDK4/6 Inhibitor Treatment to Patient Needs

A leading breast cancer specialist examines the growing role of CDK4/6 inhibitors in the adjuvant treatment of HR+/HER2- early breast cancer, citing the monarchE and NATALEE trials, and explores patient and disease-related factors that guide the decision to incorporate CDK4/6 inhibitors in this context.

  1. In the adjuvant treatment of HR+/HER2- early breast cancer, endocrine therapy has traditionally played a crucial role, with CDK4/6 inhibitors becoming more prominent in recent years through the monarchE and NATALEE trials. What factors related to the patient or disease influences the decision to utilize a CDK4/6 inhibitor in this setting?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo